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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demy-
elinating disease of the central nervous system (CNS) 
which affects primarily the white matter. The extent of 
MS burden is reflected by the degree of impairment of 
neurological and cognitive functions and by emotional 
changes, although the influence of disease characteris-
tics, such as duration, course, annual relapse rate, and 
physical disability, on cognitive and behavioral pro-
cesses is still a matter of debate [1–2, 14, 23, 34]. In MS, 
magnetic resonance imaging (MRI) often detects wide-
spread clinically silent T2 or FLAIR hyperintense lesions 
within the CNS. Besides, quantitative MRI, functional 
MRI or diffusion-weighted imaging techniques show 
abnormalities in apparently unaffected brain tissue [28, 
38]. Such alterations in normal-appearing white and 
grey matter may provoke brain dysfunction and lead to 
measurable cognitive and behavioral changes. 
The ability to make self-advantageous decisions rep-
resents an important factor for adequate social behavior 
in everyday life [19]. Decision making has been defined 
as the process through which a person forms prefer-
ences, selects and executes actions, and evaluates the 
outcome related to a selected choice [18]. The interplay 
between decision making and emotional processing has 
been studied in several neurological conditions using 
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■ Abstract  Background The pur-
pose of this study was to assess 
 decision making in patients with 
multiple sclerosis (MS) at the earli-
est clinically detectable time point 
of the disease. Methods Patients 
with definite MS (n = 109) or with 
clinically isolated syndrome (CIS, 
n = 56), a disease duration of 3 
months to 5 years, and no or only 
minor neurological impairment 
(Expanded Disability Status Scale 
[EDSS] score 0–2.5) were compared 
to 50 healthy controls using the 
Iowa Gambling Task (IGT). Results 
The performance of definite MS, 
CIS patients, and controls was com-
parable for the two main outcomes 
of the IGT (learning index: p = 0.7; 
total score: p = 0.6). The IGT learn-
ing index was influenced by the 
 educational level and the co-occur-
rence of minor depression. CIS and 
MS patients developing a relapse 
during an observation period of 15 
months dated from IGT testing 
demonstrated a lower learning in-
dex in the IGT than patients who 
had no exacerbation (p = 0.02). 
When controlling for age, gender 
and education, the difference be-
tween relapsing and non-relapsing 
patients was at the limit of signifi-
cance (p = 0.06). Conclusion Deci-
sion making in a task mimicking 
real life decisions is generally pre-
served in early MS patients as com-
pared to controls. A possible conse-
quence of MS relapsing activity in 
the impairment of decision making 
ability is also suspected in the early 
phase of MS.
■ Key words  multiple sclerosis · 
Iowa Gambling Task · decision 
making · behavior · relapse
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the Iowa Gambling Task (IGT) and skin response con-
ductance (SCR) [7–9, 19]. According to Damasio’s so-
matic marker hypothesis [10, 15], decision making is 
dependent on the emotional reactivity induced by spe-
cific environmental events, which provides a substrate 
for biasing decision by signals to a large subcortical 
frontal network including the amygdala and ventrome-
dial prefrontal cortex. Given that MS is a disseminated 
process, we had previously hypothesized that it could 
modify decision making towards more risky choices by 
different types of functional frontal disconnection or by 
MS induced cortical atrophy. Using the IGT, we were able 
to demonstrate delayed learning in decision making in 
a group of patients with relapsing-remitting (RR) and 
secondary progressive (SP) MS [22]. This finding, which 
represented impaired use of previous outcome experi-
ences in making appropriate new decisions, was associ-
ated with an inability to generate somatic markers of an 
emotional experience, as measured by the SCR. Recently, 
Nagy et al. [30] assessed decision making using the IGT 
in a small group of RRMS patients with mild disability 
(mean Kurtzke Expanded Disability Status Scale [EDSS] 
1.7) [24] and a short disease duration (mean 3.1 years). 
Their results confirmed our findings that MS patients 
show altered decision making ability, and suggested that 
this was the consequence of impaired learning ability 
and of a greater sensitivity to recent outcomes, indepen-
dently of the gains or losses experienced in the IGT.
The purpose of the present study was to provide fur-
ther information on decision making ability in MS pa-
tients with no definite neurological handicap, and who 
were active in everyday life in the professional, familial, 
and social fields. By including patients with definite MS 
and with clinically isolated syndrome [CIS], with a short 
disease duration and minor neurological disability, we 
aimed to assess decision making abilities in MS patients 
standing at the earliest accessible time point, which is 
represented by the first clinical manifestation of MS. For 
this purpose, we used the diagnostic criteria of McDon-
ald et al. [27] and revised by Polman et al. [31], which 
allow the detection of such patients by placing consider-
able emphasis on MRI-derived information. The identi-
fication of clinically silent lesions at least three months 
after a first CNS demyelinating episode allows an early 
diagnosis of definite MS. Thus, increasing the detection 
of impairments in the early stage of MS is an important 
issue that can have an effect on the therapeutic attitude 
by identifying MS patients at risk of developing a more 
severe disease with a sustained handicap.
We postulated that (1) early MS patients without dis-
ability may make more risky choices in the IGT than 
healthy subjects, (2) MS patients with a higher disease 
activity, defined by the occurrence of a relapse during an 
observation period of 15 months after performing the 
IGT, may be impaired earlier in their ability of decision 
making than stable patients (i. e., without relapses), (3) 
“risk-taking” MS patients may finally present different 
behavioral characteristics, a lower quality of life (QoL), 
or a higher perceived handicap than “non-risk-taking” 
MS patients, defined according to their IGT perfor-
mance. 
Patients and methods
■ Subjects
One hundred and sixty-five early MS patients (117 women and 48 
men) aged 18 to 65 years (mean age 35.4 years) were included in this 
transversal study. Only patients with a relapsing course, no or only 
minor neurological impairment (EDSS score 0–2.5), and with a dis-
ease duration of three months to five years were considered. Sixty-
eight patients received interferon-β 1a or 1b, 19 selective serotonin 
reuptake inhibitors for depressive symptoms, and five amantadine as 
a symptomatic treatment for fatigue. Patients were assessed once, at 
inclusion, for decision making, general cognitive functioning and be-
havior. CIS patients were tested at least three months after disease 
onset in order to apply McDonald criteria, while definite MS patients 
were tested at least six weeks after an exacerbation or corticosteroid 
treatment to avoid transient deficits or dysregulations. 
 Subsequently, all patients were followed up neurologically for 15 
months, and relapses systematically recorded and formally evaluated. 
This objective assessment is crucial, since the relapse rate during the 
first and second years of MS is considered to be an indicator of clini-
cal outcome, given the risk to develop a sustained disability later on 
[17].
 At inclusion, based on McDonald criteria [27, 31], 109 patients had 
definite MS (clinically definite MS or MS confirmed by dissemination 
in time and space using MRI) and 56 had CIS. During the observation 
period of 15 months after inclusion, 53 patients had a relapse. Of 
these, 17 were CIS at inclusion and thus evolved to definite MS ; the 
other 36 patients had already definite MS. 
 The control group consisted of 50 healthy volunteers (35 women 
and 15 men) aged 18 to 60 years (mean age 32.2), who were invited to 
participate as controls for the IGT. These normal subjects did not par-
ticipate to either the cognitive tasks or the behavioral questionnaires. 
None of the patients or controls had a history of alcohol or drug 
abuse, major psychiatric disorder (major depression, psychosis, un-
treated bipolar disorders), head trauma, other neurological disorder, 
or systemic illness. 
 The study was approved by the local university Ethics Committee 
according to the Declaration of Helsinki (1961), and all patients and 
controls signed an informed consent form before participating in this 
study.
■ Procedure
Cognitive deficits were screened in the MS group at study entry using 
tests evaluating two of the main impaired domains in MS, namely 
long-term memory and executive functions [11, 32]. The tests used 
were the Rey’s Auditory Verbal Learning Test [5], the six subtests from 
the Behavioral Assessment of the Dysexecutive Syndrome [40], and 
the Trail Making Test [33]. The presence of a cognitive impairment in 
a patient was defined by a performance two standard deviations (SD) 
below the given mean for a test. Impaired patients were those who 
failed in at least one neuropsychological measure [37]. 
 In addition, questionnaires assessing behavioral symptoms (Dys-
executive Questionnaire [DEX], Iowa Scale of Personality Change 
[ISPC]) [6, 40], fatigue (Fatigue Assessment Instrument [FAI]) [35], 
mood disorders (Hospital Anxiety and Depression scale [HAD] [42], 
and a semi-structured psychiatric interview using DSM-IV criteria), 
handicap (London Handicap Scale [LHS]) [21], and QoL (SEP-59) 
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[39] were also completed by the patient or a relative, in order to con-
trol for a possible effect of behavioral and functional factors on deci-
sion making [16].
 Decision making was assessed in MS patients and controls using 
a computerized version of the IGT, administered as described by 
Bechara et al. [7]. Subjects were told that the aim of the game was to 
win as much money as possible. Four decks (A, B, C, and D) were 
presented on a computer screen and they had to select a card from any 
of the decks using the mouse. After picking a card, the gain or loss of 
money was displayed on the computer screen, together with a corre-
sponding happy or sad face. The game consisted of 100 trials. Decks 
A and B were associated with high immediate wins, but even higher 
future losses, ending in a long-term loss (disadvantageous decks), 
whereas decks C and D were associated with low immediate wins, but 
even lower future losses, resulting in a long-term gain (advantageous 
decks). 
 For data analysis, the number of cards picked from decks A and B 
or from C and D were summed separately. Skill in decision making 
was assessed by means of a total score defined as the difference be-
tween the number of choices from advantageous or disadvantageous 
decks ([(C+D)–(A+B)]). This score ranged from –100 (choices from 
disadvantageous decks only) to +100 (choices from advantageous 
decks only). A 5-block index representing the difference between the 
number of advantageous and disadvantageous choices per block of 20 
cards was defined (B1, B2, B3, B4, B5) and rescaled to vary between –1 
and +1. A learning index aimed at measuring the ability to evolve in 
the process of decision making was defined as the difference between 
the averaged last three block indexes and first two block indexes 
(learning index = [(B3+B4+B5)/3]–[(B1+B2)/2]).
■ Statistical analysis
Statistical analyses were conducted using a STATA software package 
(Version 9.0). The distributions of some of the scores and indexes 
were not quite normal. We thus used systematically nonparametric 
tests in univariate analysis and robust estimating procedures for mul-
tivariable analysis. 
 1. We compared the definite MS, CIS and control groups for demo-
graphic variables by means of a 3-way Kruskall-Wallis test (for age) 
and of chi2 (for gender and education). We then compared the defi-
nite MS and CIS groups for clinical variables by means of a Wilcoxon 
test (for disease duration and EDSS score) and of chi2 (for immuno-
modulatory and antidepressive treatment, diagnosis of minor depres-
sion, and occurrence of a relapse). The performances in neuropsycho-
logical and behavioral assessments were compared between definite 
MS and CIS patients by means of chi2 (for the proportion of cognitive 
deficits, depressed and anxious symptoms, dysexecutive behaviors 
and fatigue) and Wilcoxon tests (for behavioral changes, and scores 
of handicap and QoL).
 2. We compared the definite MS, CIS and control groups for the 
two main outcomes of the IGT (the total score and the learning index) 
by means of a 3-way Kruskall-Wallis test. We also compared patients 
who experienced a relapse during the 15-months follow-up and those 
who did not, globally and separately for definite MS and CIS using 
Wilcoxon tests. 
 3. Focusing then on patients only (definite MS and CIS), we inves-
tigated if associations could be found between the learning index and 
the covariates. We used Spearman correlations (for age, disease dura-
tion, EDSS score, behavioral changes, and scores of handicap and 
QoL) or Wilcoxon tests (for gender, education, immunomodulatory 
treatment, diagnosis of minor depression, use of antidepressants, pro-
portion of cognitive deficits, depressed and anxious symptoms, dys-
executive behaviors and fatigue).
 4. Comparison between patients who experienced a relapse dur-
ing the 15-months follow-up and those who did not was tested con-
trolling for potential confounders and stratifying for phenotype. For 
this test, a multivariable robust linear regression model was built for 
the learning index as a dependent variable, and the occurrence of a 
relapse, the phenotype at baseline, age, gender, education, occurrence 
of immunomodulatory treatment and diagnosis of minor depression 
as independent variables. All these covariates were entered in the 
model. A backward procedure was used to obtain the final model. The 
criterion used to keep a covariate in the final model was a p-value 
< 0.10. The residuals from the final model were plotted against pre-
dicted values and against each regressor to check the validity of the 
model (diagnostic plots). 
 5. We also repeated the points 3 and 4 for the IGT total score.
Results
Definite MS patients, CIS patients and controls were 
comparable in terms of gender (respectively, 67 %, 79 % 
and 70 % of women; p = 0.3) and education (respectively, 
86 %, 87 % and 84 % had at least high-school education; 
p = 0.4) but not for age (respectively, 34 [SD 9.2], 37.9 [SD 
8.3] and 32.2 [SD 11.1]; p < 0.001). Clinical and neuro-
psychological characteristics of MS and CIS patients 
(disease duration, EDSS score, occurrence of a relapse, 
use of immunomodulators, diagnosis of minor depres-
sion, use of antidepressants, prevalence of cognitive 
deficits) are given in Table 1, and the behavioral, handi-
Definite MS
(n = 109)
CIS
(n = 56)
p-value
Disease duration (years) (mean [SD])  2.8 (1.9)  1.4 (1.3) 0.0001
EDSS score (mean [SD])  1.82 (0.4)  1.66 (0.4) 0.01
Patients relapsing after inclusion (%) 33 30 0.7
Immunomodulators (% of patients) 54 16** < 0.0001
Diagnosis of minor depression (% of patients)  8 11 0.6
Antidepressants (% of patients)* 10 16 0.3
Cognitive impairment (% of patients) 34 25 0.2
* Antidepressants were used for minor depression according to the DSM IV criteria and mood swing since major 
depression was an exclusion criterion
** Nine CIS patients fulfilling McDonald criteria for a dissemination in space of the lesions were receiving low 
doses interferon-beta 1a (Rebif® 1 x  22 μg weekly), which was at that time registered in Switzerland for the 
treatment of possible MS
Table 1  Clinical variables for definite MS and CIS pa-
tients at inclusion, concomitantly to the IGT testing 
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cap, and QoL scores are presented in Table 2. Based on 
published normative data [5, 33, 40], 51 patients (31 %) 
of the complete sample (definite MS and CIS) displayed 
an impaired performance in the neuropsychological as-
sessment.
Comparing definite MS and CIS patients, disease du-
ration, the percentage of patients treated with immuno-
modulators, and the number of behavioral modifica-
tions in the ISPC were the only clinical variables showing 
a statistical difference. The prevalence of cognitive defi-
cits was comparable between definite MS and CIS pa-
tients, as well as between relapsing (34 %) and stable 
(29 %) patients (p = 0.6). More specifically, verbal learn-
ing abilities (RAVLT) were similar (p = 0.6), as well as 
performances of attention/processing speed (TMT part 
A: p = 0.6; TMT part B: p = 0.8). However, subgroups dif-
fered according to executive scores which were higher in 
stable than in relapsing patients (p = 0.02). 
■ Decision making ability in early MS patients 
(definite MS and CIS), and controls
The [(C+D)–(A+B)] total score was 7.9 (SD 33.7) in the 
control group and 4.0 (SD 28.4) in the patients’ group 
but this difference was not statistically significant 
(p = 0.4).The 5-block index increased over time in both 
groups, implying that subjects were able to recognize 
that decks A and B were disadvantageous. The mean of 
the first two block indexes was negative and comparable 
in controls and MS patients (–0.06 [SD 0.27] and –0.09 
[SD 0.21] respectively; p = 0.3), indicating a higher num-
ber of disadvantageous choices in both groups. The 
mean over the last three blocks was greater for the con-
trol group than for MS patients (0.18 [SD 0.47] and 0.13 
[SD 0.40], respectively) but the difference was not sig-
nificant (p = 0.4). Learning index was 0.24 (SD 0.44) in 
the control group and 0.21 (SD 0.38) in the MS group 
and the difference was not statistically significant 
(p = 0.7). 
■ Decision making ability in definite MS patients, CIS 
patients and controls
The [(C+D)–(A+B)] total score was 7.9 (SD 33.7) in the 
control group, 4.1 (SD 29.7) in the definite MS group, and 
3.9 (SD 29.5) in the CIS group. This difference between 
the three groups was not statistically significant (p = 0.6). 
The learning index was 0.24 (SD 0.44) in the control 
group, 0.22 (SD 0.38) in the definite MS group and 0.19 
(SD 0.37) in the CIS group. This difference between the 
three groups was also insignificant (p = 0.7) (Table 3). 
The 5-block index increased over time in all three groups 
( ≤ 1) and the learning index was significantly > 0 ac-
cording to the 95 %CI, indicating that in average there 
was a trend toward a recognition of the decks A and B as 
disadvantageous by all patients and controls (definite 
MS: 95 %CI [0.09–0.29]; CIS : 95 % CI [0.15–0.30]; con-
trols: 95 %CI [0.11–0.36]).
■ Decision making ability and MS clinical activity 
The [(C+D)–(A+B)] total score was –0.87 (SD 26.41) in 
the group composed of the 53 MS patients who experi-
enced a relapse during the 15 months following their 
inclusion and 6.36 (SD 29.22) in stable (i. e., no relapse) 
CIS and MS patients. This difference was not significant 
(p = 0.1), but the learning index differed between the two 
groups (0.12 [SD 0.38] in relapsing patients vs. 0.26 [SD 
0.37] in stable patients; p = 0.02) (Table 3). Stratifying by 
the phenotype showed on the one hand that stable defi-
nite MS had nearly the same learning index than stable 
CIS and controls (respectively 0.27 [SD 0.38], 0.23 [SD 
0.37] and 0.24 [SD 0.44]), and on the other hand that 
Table 2  Percentages of definite MS and CIS patients with pathological scores in 
the HAD, DEX, and FAI. Number of acquired behavioral traits and scores of handicap 
and QoL
Definite MS
(n = 109)
CIS
(n = 56)
p-value
Behavior
 HAD-A > 8 (%) 49 56 0.4
 HAD-D > 8 (%) 20 15 0.4
 DEX patients > 38 (%) 16  9 0.2
 DEX relatives > 24.5 (%) 46 39 0.4
 FAI severity > 4.26 (%) 57 50 0.4
 ISPC number of behavioral 
 modifications
 6.5 (5.8)  3.2 (3.9) < 0.001
Handicap and QoL
 LHS  9.0 (3.3)  8.2 (2.9) 0.5
 SEP-59 46.4 (11.0) 44.7 (9.7) 0.3
HAD Hospital Anxiety and Depression scale; DEX Dysexecutive Questionnaire; FAI 
Fatigue Assessment Instrument; ISPC Iowa Scale of Personality Change; LHS London 
Handicap Scale
Table 3  [(C+D)-(A+B)] total score and learning index for the definite MS, CIS 
patients and controls, and in stable vs. relapsing patients 
Total score
(mean [SD])
Learning index
(mean [SD])
Definite MS (n = 109) 4.1 (28.1) 0.2 (0.4)
CIS (n = 56) 3.9 (29.5) 0.2 (0.4)
Controls (n = 50) 7.9 (33.6) 0.2 (0.4)
p-value 0.6 0.6
Stable patients (n = 112) 6.4 (29.2) 0.3 (0.4)
Relapsing patients (n = 53) –0.9 (26.4) 0.1 (0.4)
p-value 0.1 0.02
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relapsing definite MS patients had almost the same 
learning index as relapsing CIS (respectively 0.13 [SD 
0.39] and 0.10 [SD 0.35]). The learning index did not sig-
nificantly differ between relapsing and stable patients, 
both in the definite MS (p = 0.1) and the CIS (p = 0.1) 
groups. 
■ Associations between decision making ability and the 
covariates in the patients’ group
Few variables were found to be associated with the learn-
ing index. In the whole early MS group (definite MS and 
CIS), women had a smaller learning index than men but 
the difference was not significant (0.19 [SD 0.35] for 
women vs. 0.27 [SD 0.44] for men; p = 0.1). Patients with 
a higher educational level (> 12 years of education or 
academic background) had a higher learning index (0.35 
[SD 0.41]) than patients with a lower educational level 
(0.17 [(SD 0.36]) (p = 0.006). A trend to an association 
was also found between the learning index and the pres-
ence of a minor depression according to the DSM IV 
criteria (0.06 [SD 0.31] for depressed patients and 0.23 
[SD 0.38] for nondepressed patients; p = 0.07). When ex-
cluding patients treated with antidepressants from the 
IGT analysis, the learning index became similar between 
definite MS, CIS, and controls (p = 0.4), as well as be-
tween relapsing and stable patients (p = 0.2). Finally, fo-
cusing on stable patients only, risky decision making in 
the IGT ([(C+D)–(A+B)] total score > 0) was associated 
with higher scores in the DEXp (25.3 [16.3] for risk tak-
ers vs. 16.7 [9.5] for no-risk takers; p = 0.01) and DEXr 
(27.5 [11.9] vs. 21.2 [10], respectively; p = 0.01), as well as 
with a slightly higher number of behavioral changes in 
the ISPC (6.8 [6.5] vs. 4.3 [4.3], respectively; p = 0.6). No 
association was found with cognitive impairment (34 % 
vs. 26 %, p = 0.4).
■ Multivariable model for the IGT learning index
Potential confounders for the relation between the learn-
ing index and disease activity were selected a priori (see 
statistical analysis in the Methods section). In the final 
model, after adjustment for age, gender, and education, 
the estimated difference in the learning index between 
stable and relapsing patients was 0.12, a value which is 
at the limit of significance (p = 0.06). Phenotype, pres-
ence of an immunomodulatory treatment and diagnosis 
of minor depression were not retained in the final model 
(p-value > 0.1). The diagnostic plots (as well as formal 
tests) showed that no interaction was necessary. 
The same analytical frame was followed for the 
[(C+D)–(A+B)] total score, and the results obtained 
were insignificant (p = 0.2). 
Discussion
We assessed decision making ability in a large sample of 
definite MS and CIS patients standing in the early course 
of the disease, some of whom being at the earliest clini-
cally detectable stage of MS [27, 31]. Our main finding is 
that, in such an early MS population, the ability to learn 
to avoid disadvantageous decks in the IGT does not dif-
fer from that of controls and that, in contrast to more 
advanced MS [22], decision making seems to be pre-
served in the early stages of the disease. Our results dif-
fer from those of Nagy et al. [30] who found impaired 
decision making in MS patients with mild disability. 
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However, they tested a slightly more advanced MS popu-
lation (all their patients already had definite MS and 
disease duration was one year longer on average) and 
the presence of IGT difficulties in their study group 
might be related to the evolution of the MS process. 
Indeed, Nagy et al. [30] hypothesized that decision 
making difficulties at an early stage of MS may reflect 
sub-clinical pathology. The observation that the devel-
opment of a relapse within the 15 months following the 
test was, in some extent, related to the IGT performance 
after adjustment for demographic characteristics gives 
weight to their hypothesis. In fact, these relapsing pa-
tients demonstrated a lower learning index in the IGT in 
comparison to stable patients who switched more clearly 
from disadvantageous to advantageous decks during the 
task. The role of the activity itself, of changes in execu-
tive functions (measured by the BADS) and mood (as 
reflected by the use of antidepressants) is however dif-
ficult to disentangle. 
The behavioral mechanisms by which difficulties in 
decision making occur in MS and more generally is still 
debated. According to Maia & McLelland [26], con-
sciously accessible knowledge may induce overt behav-
ior and verbal reports, which influence directly decision 
making; the use of non-conscious somatic markers may 
not be necessary in that context. For Nagy et al. [30], 
poor decision making was rather the consequence of an 
impaired learning process across trials and of a greater 
sensitivity to recent outcomes, independently of gains or 
losses. Finally, we have previously suggested an impair-
ment of emotional experience instead of cognitive 
changes as an inducing mechanism [22]. In the present 
work, IGT performances were associated with DEX 
scores in stable patients, giving weight to our previous 
hypothesis of a link between decision making and emo-
tional behavior. Moreover, an interesting finding was 
that minor depression was one of the two covariates that 
significantly influenced the IGT results (the other one 
being education). The MS literature provides a couple of 
other studies showing that depressed MS patients per-
formed significantly worse on executive types of cogni-
tive tasks that could be construed as overlapping some-
what in the constructs measured by the IGT. Specifically, 
Arnett et al. reported lower performances in a depressed 
group of MS patients in comparison to nondepressed 
MS patients on a planning task [4], and showed the same 
pattern for a working memory task that is considered 
executive in nature [3]. Besides, Landro et al. [25] re-
ported that depressive symptoms also accounted for 
slowed information processing speed in MS patients. 
Impairment in decision making has generally been 
described in focal frontal lesions [9] but was also found 
in more diffuse neurological or psychiatric diseases, in 
which vulnerable widespread networks may be respon-
sible for a decreased decision making efficacy [29, 36]. 
This vulnerability in MS could be related to transient 
inflammation and/or to a more chronic demyelinating 
and degenerative process. MRI measurements of cere-
bral lesion load and inflammatory activity, which were 
not performed in the present evaluation, would provide 
interesting complementary data to analyze in future 
studies on decision making in MS more focalized on the 
understanding of underlying mechanisms. 
The variability of the IGT responses obtained in the 
normal population may have been a limiting factor for 
detecting more significant differences between the 
groups we have tested. Indeed, variability in the IGT per-
formances is a classical finding in healthy controls and 
inter-individual differences in brain mechanisms related 
to gender [12], age [20] or personality traits [16, 41] may 
possibly explain this phenomenon. However, the asso-
ciation between IGT performances and DEX scores in 
stable patients might also reflect such behavioral vari-
ability in the MS population. Such transversal study is 
obviously a first step, and decision making should be 
tested in follow-up analyses, with validated parallel ver-
sion of IGT. We are currently preparing a longitudinal 
study in MS patients to evaluate associations between 
disease progression and modifications of performances 
in IGT. 
In conclusion, the results obtained in a well defined 
population of early MS patients, some of whom were 
tested at the first detectable time point in their disease 
course, suggest that the ability of decision making is 
generally preserved in early MS but also argue for a pos-
sible association of MS activity with the impaired pro-
cess of decision making. Further complementary analy-
ses including MRI studies should be performed to give 
a more sensitive picture of the extent of the burden sec-
ondary to MS, and to confirm this observation. 
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